Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT01908504
Official study title

Adaptive Pet Study

Study summary

The purpose of this study is to determine the benefit of using positron emission tomography (PET) in addition to the standard (computed tomography) CT to plan radiation therapy for cancer treatment. The information from the PET-CT may allow the investigators to change the radiation plan or the delivery of the radiation to the tumor/tumor site such as the total dose of radiation or the size of the area to receive further radiation. Presently the use of PET scans to adjust radiation therapy during radiation treatment is not standard of care and is being investigated in this study.

Ask AI to explain this study
Start here

Key things to know

Main goalOther

This describes the study’s primary purpose.

What is being studiedPET-CT

The study team can explain what participation involves.

Who it may be forHead and Neck Cancers · Lung and Esophagus Cancers

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Apr 26, 2023 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Duke University

Study sponsor

01
Study overview

What this study is about

Purpose
Other
Study type
Interventional
Phase
Not applicable
Sponsor
Duke University
Interventions being studied
Other: PET-CT
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach
Radiation therapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Pathologically (histologically or cytologically) proven diagnosis of carcinoma
  • Patients with local or regional nodal disease are eligible.
  • Zubrod Performance Status 0, 1, or 2.
  • Age ≥ 18
  • Negative serum pregnancy test for women of child bearing potential
  • Patient must sign study-specific informed consent prior to study entry.
Reasons someone may not be able to joinExclusion criteria
  • No gross disease visible on imaging at the start of radiotherapy
  • Contraindication to PET
  • Complete response by PET achieved with pre-radiation therapy treatment (surgery or chemotherapy)
  • Breast feeding

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Duke University Medical CenterDurham, North Carolina

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 26, 2023. Always confirm current availability with the study team.

View original record ↗